Quality of Life among Persons with Prostate Cancer

Main Article Content

Lalida Noppakun
Rujadhorn Indratula
Nuttamon Vuttanon


Background and Objectives: Cancer and its treatment often negatively affect patients’ quality of life (QOL). A study of QOL among persons with prostate cancer may help healthcare professionals in making an appropriate care plan for promoting patients’ QOL. This research aimed to explore quality of life among persons with prostate cancer and to compare their QOL classified by age, educational level, staging of disease, and treatments.

Methods: This cross-sectional descriptive design recruited 127 participants from persons with prostate cancer admitted at a university hospital between January and June 2017. The research instrument used was a set of questionnaires, which consisted of the Demographic data questionnaire and the Functional Assessment of Cancer Therapy-Prostate-Thai questionnaire (FACT-P). Data were analyzed using descriptive statistics and the Kruskal-Wallis test.

Results: The mean score of an overall QOL among persons with prostate cancer was at a high level (120.78±14.72). Based on the test, the participants receiving chemotherapy had an overall significantly different QOL from the participants treated with other methods (p=.039) by accounted was at a moderate level (100.33±19.22). Considering each aspect, the mean scores of QOL in physical well-being aspect and cancer specific aspect were at a moderate level (17.67±4.04, 28.00±4.59, respectively).

Conclusion: The result of this study revealed that the participants receiving chemotherapy had an overall QOL less than the participants treated with other methods. This finding suggests healthcare professionals should focus on care planning in order to reduce symptoms in persons with prostate cancer undergoing chemotherapy to improve the patients’ QOL.


Download data is not yet available.

Article Details

Original Articles


1. World Cancer Research Fund International. Prostate cancer statistics [on line] 2018. [Accessed August 11, 2019]. Available from https://www.wcrf.org/dietandcancer/cancer-trends/prostate-cancer-statistics
2. American Cancer Society. Cancer facts & figures 2017. Georgia: American Cancer Society, 2017.
3. Cancer Research UK. Prostate cancer statistics [on line] 2017. [Accessed November 1, 2017]. Available from https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer
4. National Cancer Institute. Hospital-based Cancer Registry 2016. Bangkok: Information Technology Division, National Cancer Institute, 2016
5. National Cancer Institute. Hospital-based Cancer Registry 2014. Bangkok: Information Technology Division, National Cancer Institute, 2014.
6. American Cancer Society. Survival rates for prostate cancer. [on line] 2019. [Accessed September 11, 2019]. Available from https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/survival-rates.html.
7. Watts S, Leydon G, Birch B, Prescott P, Lai L, Eardley S, et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open 2014; 4(3): e003901.
8. Smith A, Hyde YM, Stanford D. Supportive care needs of cancer patients: A literature review. Palliat Support Care 2015; 13:1013-7.
9. Eton DT, Lepore SJ. (2002). Prostate cancer and health-related quality of life: a review of the literature. Psychooncology 2002; 11: 307-26.
10. Prezioso D, Galasso R, Di Martino M, Iapicca G. Prostate cancer treatment and quality of life. Results Cancer Res 2007; 175: 251-65.
11. van Tol-Geerdink JJ, Leer JW, van Oort IM, van Lin EJ, Weijerman PC, Vergunst H, et al. Quality of life after prostate cancer treatments in patients comparable at baseline. Br J Cancer 2013; 108: 1784-89.
12. Bergius S, Torvinen S, Muhonen T, Roine RP, Sintonen H, Taari K. Health-related quality of life among prostate cancer patients: real-life situation at the beginning of treatment. Scand J Urol 2017; 51: 13-9.
13. Pinkawa M, Fischedick K, Gagel B, Piroth MD, Asadpour B, Klotz J, et al. Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment. BMC Cancer 2009; 9: 296.
14. Hampson LA, Cowan JE, Zhao S, Carroll PR, Cooperberg MR. Impact of age on quality-of-life outcomes after treatment for localized prostate cancer. Eur Urol 2015; 68: 480-6.
15. Klein J, Ludecke D, Hofreuter-Gatgens K, Fisch M, Graefen M, von dem Knesebeck O. Income and health-related quality of life among prostate cancer patients over a one-year period after radical prostatectomy: a linear mixed model analysis. Qual Lif Res 2017; 26: 2363-73.
16. Kao YL, Tsai YS, Ou FY, Syu YJ, Ou CH, Yang WH, et al. Determinants of quality of life in prostate cancer patients: a single institute analysis. Urol Sci 2015; 26: 254-8.
17. Lepore SJ, Helgeson VS, Eton DT, Schulz R. Improving quality of life in men with prostate cancer: a randomized controlled trial of group education interventions. Health Psychol 2003; 22: 443–452.
18. Chambers SK, Ferguson M, Gardiner RA, Aitken J, Occhipinti S. Intervening to improve psychological outcomes for men with prostate cancer. Psych oncology 2013; 22: 1025-34.
19. อัญพัชร์ พุฒิศราเศรษฐ์, สุพร ดนัยดุษฎีกุล, อรพรรณ โตสิงห์, กิตติพงษ์ พินธุโสภณ. ปัจจัยที่มีความสัมพันธ์กับคุณภาพชีวิตของผู้ป่วยมะเร็งต่อมลูกหมากที่ได้รับการผ่าตัดต่อมลูกหมากออกทั้งหมด. วารสารพยาบาลทหารบก 2560; 18: 100-6.
20. ธีรวุฒิ เอกะกุล. ระเบียบวิธีวิจัยทางพฤติกรรมศาสตร์และสังคมศาสตร์. อุบลราชธานี:วิทยาอ๊อฟเซท, 2550.
21. Park SA, Chung SH, Lee Y. Factors influencing the quality of life of patients with advanced cancer. Appl Nurs Res 2017; 33:108-12.
22. Charalambus A, Kouta C. Cancer related fatigue and quality of life in patients with advanced prostate cancer undergoing chemotherapy. Biomed Res Int 2016; 2016:3989286.
23. Dehkordi A, Heydarnejad MS, Fatehi D. Quality of life in cancer patients undergoing chemotherapy. Oman Med J 2009; 24: 204-7.
24. โสภิต ก่อพูนศิลปะ, และทิพาพร พงษ์เมษา. คุณภาพชีวิตของผู้ป่วยหญิงมะเร็งเต้านมในช่วงการรักษาด้วยยาเคมีบำบัดสูตร Fluorouracil, Doxorubicin และ Cyclophosphamide (FAC). สงขลานครินทร์เวชสาร 2560; 35: 374-84.